AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04368494 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week home based exercise
Description: Patients allocated to the exercise arm will be prescribed a home-based walking exercise programme consisting of 30 minutes of walking on 5 days per week at an RPE in the range of 12-14 (somewhat hard). Each patient's heart rate range will be established during the baseline exercise test by recording the heart rate response at the required RPE target range. This will be provided to each patient to use in conjunction with the activity monitor they will be given to wear on their non-dominant wrist. The monitor reports heart rate and records daily steps, distance and activity duration.
Study NCT05548712 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse Electromagnetic Field
Description: Subjects will receive PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions and do the home-based exercise twice a week for 8 weeks.
Study NCT05548712 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Pulse Electromagnetic Field
Description: Subjects will receive sham PEMF treatment with the duration of 8 weeks, twice a week with total 16 treatment sessions and do the home-based exercise twice a week for 8 weeks.
Study NCT06452641 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Jones technique
Description: Strain counter strain technique also known as Jones technique will be performed with the patient lay supine on the treatment table, taking them to a position-of-comfort by extending, side-bending, and rotating the head away (ESARA) from the TP until the TP pain has reduced. Continues to monitor, maintaining the patient's position for 90 seconds. After 90 seconds has elapsed, the patient's head should be slowly and passively returned to a neutral position with 3 sessions/week for 6 weeks. In essence, the TP should be relieved by placing the patient in a position of comfort, holding this position for 90 seconds, and slowly returning the patient to a neutral position.
Study NCT05600088 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CryoTherapy System (CTS)
Description: local cryotherapy of coronary high-risk plaque lesions using the CTS consisting of a semi-compliant balloon and a console controlling the temperature of cryotherapy
Study NCT06267768 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Various intensities of inspiratory muscle training
Description: Each participant will be asked to perform the lung function test to measure the maximal inspiratory pressure (MIP) after including the study. After the baseline measurement, all participants will be requested to use a nose clip to hold the nose and breathe with the mouth through a pressure threshold inspiratory loading device (POWERbreathe, KH2, England). The inspiratory pressure will be set at 30%, 40%, 50%, 60%, 70%, or 80% of their MIP, in random order. Each MIP intensity protocol consists of 10 breaths. Resting will be allowed between different protocols of contraction intensity (% MIP). During the test, sternocleidomastoid muscle activity will be measured with surface electromyography (sEMG) and diaphragm thickness will be used to assessed with ultrasonography.
Study NCT06452641 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cross-friction massage
Description: Group B will get cross friction massage for 15-20 mins. Participants will be treated 3 times per week for 6 weeks. Pre and Post-treatment readings will be taken in 1st session and 6th week respectively.
Study NCT05743270 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CCRT(concurrent chemoradiation therapy)
Description: CCRT consisting of intensity modulated radiation therapy combined with a cis-platinum
Study NCT05743270 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: carboplatin and paclitaxel
Description: chemotherapeutic agents
Study NCT05224024 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Retzius-repairing robot-assisted radical prostatectomy
Description: Repairing the retzius space which is opened during the standard robot assisted radical prostatectomy.
Study NCT06444984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fasting Trial
Description: Participants will report fasted and consume popcorn (6 cups popped microwave popcorn), soda (32 oz Coke-a-cola), and candy (2.17 oz of Skittles) in the morning.
Study NCT06444984 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fed Trial
Description: Participants will report fasted and first consume a high-fat meal (Jimmy Deans) in the morning. After a three-hour break, participants will consume popcorn (6 cups popped microwave popcorn), soda (32 oz Coke-a-cola), and candy (2.17 oz of Skittles).
Study NCT05532501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Oxytocin
Description: Administer oxytocin (24 IU) orally, 6 individual 0.1 ml puffs (4 IU/0.1ml) on the tongue (lingual), one every 30 seconds
Study NCT04751994 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iron drops/Ferrous sulphate
Description: participant will consume daily drops of iron
Study NCT04751994 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo drops
Description: Participants will consume daily drops of placebo
Study NCT05743270 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: nivolumab
Description: anti-PD1 monoclonal antibody
Study NCT05532501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intranasal Oxytocin
Description: Administer oxytocin (24 IU) intranasally, 6 individual 0.1 ml puffs (4 IU/0.1ml), three puffs per nostril one every 30 seconds
Study NCT05532501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral placebo
Description: Administer placebo orally, 6 individual 0.1 ml puffs on the tongue (lingual), one every 30 seconds.
Study NCT05532501 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal placebo
Description: Administer placebo intranasally, 6 individual 0.1 ml puffs, three puffs per nostril one every 30 seconds
Study NCT05909670 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Advice and Support Text and Telephone (FASTT) program
Description: The Family Advice Support Text and Telephone (FASTT) service is a telehealth model that provides on-demand, evidence-based advice and support to reduce child behavior problems, address concerns about child development, and help manage stress for caregivers of children with DD. By using text and telephone, which are widely available without disparities in access by race, ethnicity, or socioeconomic status, FASTT overcomes barriers associated with videoconferencing which requires dependable Internet and familiarity with technology use. FASTT allows support to be delivered at times and locations that are convenient for the caregiver.
Study NCT05522582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate tablets
Description: Tablets with 5mg methotrexate are taken orally twice a week during the whole course of radiotherapy
Study NCT05522582 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-PD-1 monoclonal antibody
Description: Anti-PD-1 monoclonal antibody 200mg is given intravenously every 3 weeks from the first day of radiotherapy until or after the end of treatment.
Study NCT05522582 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 6～15MV X-ray, 2Gy/time, 5times/week. The duration of radiotherapy depends on the target lesion.
Study NCT05707442 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stent Implantation
Description: Aspirin (100 mg) and clopidogrel (75 mg) were administered 3-5 days before endovascular treatment. The endovascular procedure was performed under general anesthesia. Intravenous heparin was administered during the stent procedure to increase the activated clotting time to > 250 s. An 8F guiding catheter was delivered to the internal jugular vein near the skull base. A 6F Navien intermediate guide catheter was then placed into the distal transverse sinus near the torcula through the 8F guiding catheter. A microguidewire was navigated across the stenosis using a microcatheter, followed by the deployment of a self-expanding stent (eg, Precise or Wallstent) adjusted to the normal sinus venous diameter adjacent to the stenosis. Venography and manometry were performed after the procedure. Postoperatively, all patients received dual antiplatelet medications for 3 months and then received a single antiplatelet (either aspirin or clopidogrel).
Study NCT05707442 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetazolamide-based medical therapy
Description: The medical treatment consisted of acetazolamide (0.5-4 g/day) and short-term mannitol (bolus of 0.25-1 g/kg body weight) for a duration of about 1 week or repeated lumbar punctures to reduce intracranial pressure (20 mL each), as well as analgesics for headaches. The initial dosage of acetazolamide was 0.5 g daily in two divided doses, followed by dosage increases of one tablet every week up to a maximum dosage of 4 g/day. The dosage escalation was stopped if the participant had papilledema grade \<1 in both eyes, unless the presence of other symptoms such as headache or tinnitus suggested that the dosage escalation should continue. The dosage for the participants who were unable to tolerate the study drug was decreased gradually to a minimum of one half tablet daily.
Study NCT05707442 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Weight loss
Description: The weight loss program included a low-calorie diet (≤425 kcal/day) with a target weight loss of approximately 5-10%.
Study NCT05385367 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Regional anesthetic
Description: Patient having just the nerve block for surgery
Study NCT05385367 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: General anesthetic
Description: Patient having just general anesthetic ie. 'go completely under' for surgery
Study NCT05385367 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Combined general anesthetic and regional anesthetic
Description: Patient having a combination of a nerve block and general anesthetic for surgery
Study NCT05601219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADA-011
Description: ADA-011 will be administered intravenously (IV) Q3W on a 21-day cycle.
Study NCT05601219 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD(L)-1 inhibitor
Description: PD(L)-1 inhibitor will be administered intravenously (IV) Q3W.
Study NCT06056895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT06056895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT06056895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT/MRI
Study NCT06056895 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo CT/MRI
Study NCT06056895 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Retifanlimab
Description: Given IV
Study NCT06056895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tuparstobart
Description: Given IV
Study NCT06056895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verzistobart
Description: Given IV
Study NCT05259072 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 99m-technetium pyrophosphate scintigraphy
Description: Imaging test
Study NCT05557799 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photobiomodulation
Description: The treatment group will receive four consecutive applications, using laser diode DMC (808 nm), 4J per point, 100mW of power, 510mW/cm², beam area of 0.2cm², 8 sites in the external vagina, for 40s in each site, once per week for 4 weeks.
Study NCT05557799 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Photobiomodulation
Description: The Placebo Group will receive the same four consecutive applications, but with the laser turned off.
Study NCT05023772 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Laser Ablation
Description: MR Guided laser ablation therapy
Study NCT05023772 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Precise delivery of radiation to spinal tumor
Study NCT05023772 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI guided laser ablation
Description: Surgery will take place in intraoperative suite to include operating room and MRI scanner
Study NCT04729387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Alpelisib will be administered at 200 mg orally once daily following food on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28-day cycle
Study NCT04729387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: Olaparib will be administered at 200 mg orally twice daily irrespective of meals on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28-day cycle.
Study NCT04729387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel will be administered at 80 mg/m2 as an intravenous infusion weekly during a 28-day treatment cycle, starting on Cycle 1 Day 1, and on Day 8, Day 15 and Day 22 of every cycle thereafter
Study NCT04729387 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated liposomal doxorubicin (PLD)
Description: PLD will be administered at 40-50 mg/m2 (physician discretion) as an intravenous infusion once every 28-days in a 28 day treatment cycle, starting on Cycle 1 Day 1
Study NCT04656691 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bamlanivimab
Description: Participants that test positive for COVID-19 may be eligible to receive an in-home infusion of bamlanivimab by a registered nurse. This infusion will last approximately 1 hour followed by 1 hour of observation.
Study NCT04943185 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: XEN gel microstent implantation
Description: Two differents implantation :~Ab interno : Operative intervention Ab externo : Slit lamp intervention
Study NCT04889456 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implementation standardised laparoscopic right hemicolectomy with proctoring
Description: Implementation standardised laparoscopic right hemicolectomy with proctoring
Study NCT04889456 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implementation standardised laparoscopic right hemicolectomy without proctoring
Description: Implementation standardised laparoscopic right hemicolectomy without proctoring
Study NCT05071456 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Collects of skin's hydration
Description: Collects of skin's hydration will be made by using patch using electrochemistry.
Study NCT05071456 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Collects of skin's hydration
Description: Collects of skin's hydration will be made by using patch using electrochemistry.
Study NCT04104945 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: De-intensified chemoradiotherapy
Description: Radiotherapy to a dose of 60 Gy to the primary tumour and involved lymph nodes and 54 Gy to subclinical regions at risk in 30 fractions. Reduced volume of elective nodal radiation.
Study NCT06221930 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: attexis
Description: Participants will receive access to the digital health intervention attexis in addition to TAU.
Study NCT05084235 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Empagliflozin 10 MG
Description: Patients are randomized 1:1 to receive either Empagliflozin or matching placebo for 180 days
Study NCT05084235 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matches the active drug in appearance, odor and labelling
Study NCT04767581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: KHK7791
Description: oral administration
Study NCT04767581 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral administration
Study NCT05704023 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminder to exercise
Description: Exercise support: Daily, at 7 p.m. patients will get a notification with a reminder to exercise. The app includes photographs of exercises, with instructions, that patients can look at and read if they forget which exercises they need to do and how.
Study NCT05612061 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Indigenous Recovery Planning
Description: The Indigenous Recovery Planning (IRP) intervention consists of a 6-week group-based intervention. Each of the 6 weekly sessions is delivered by a community member facilitator. Facilitators lead the group through a series of culturally adapted relapse prevention exercises designed to change their substance use.~Focus areas for the 6 sessions are: 1) introduction and goal setting; 2) relapse and recovery; 3) craving, mindfulness, and self-compassion; 4) coping with trauma and stress; 5) enlisting social support for recovery; 6) envisioning and planning for the future.
Study NCT05675722 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: biologic vaginal-construct implantation
Description: biologic Tissue Engineered Vagina (TEV), which provides an epithelial layer for the luminal aspect and a smooth muscle layer for protecting the openness of the hollow tube, mimicking the cellular orientation and architecture of the vagina. Autologous cells isolated from vagina/vulva remnants offset any potential for immunological rejection.
Study NCT06112262 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: Comparison between heparin and hirudin
Study NCT06012825 — intervention group
Intervention type: BEHAVIORAL
Intervention: Physical Activity
Description: The program will consist of 2 consecutive rounds of 12-week programming, 2x/week for 60 minutes on a Health Insurance Portability and Accountability Act (HIPAA)-compliant Zoom account. The PA program will be structured to ensure equivalent PA doses are provided. This will be done by allocating time to a warm-up (5 min), an introduction and demonstration of the activity (5 min), the PA (30 min), cool down and stretching (5 min). Time will also be devoted for interaction to develop rapport, transition to the next activity, and to handle internet connectivity issues (15 min).
Study NCT06311721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABP 234
Description: Intravenous administration
Study NCT04733833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VB-201 + Standard of care
Description: Daily oral administration of VB-201- 160 mg (80 mg BID) with standard of care
Study NCT06198868 — intervention group
Intervention type: PROCEDURE
Intervention: Operable
Description: Enrolled patients capable of surgical treatment
Study NCT05776199 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Sonoelastography, tensiomyography and mechanosensitivity
Description: To observe the differences between the different trigger points of the levator scapulae muscle by means of different diagnostic options.
Study NCT05776199 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sonoelastography, tensiomyography and mechanosensitivity
Description: To observe the differences between the different trigger points of the levator scapulae muscle by means of different diagnostic options.
Study NCT05545215 — intervention group
Intervention type: DEVICE
Intervention: Dexyane Med
Description: Dexyane MeD® is a non-sterile topical cream, for external use only, available in 30 mL or 100 mL tubes (also available in sample model 5mL tubes).
Study NCT04733833 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care
Study NCT04936386 — intervention group
Intervention type: BEHAVIORAL
Intervention: Survey
Description: The survey is composed of 4 different sections: the first section included questions about demographic data of participants; the second part evaluated responders' knowledge about FGM; the third section focused on participants' working experience with patients affected by FGM and personal attitude related to this topic.
Study NCT06510881 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Rhinoplasty with or without cleft alveolus repair
Description: * Group (A) : Correction of nasal deformity will be carried out using costochondral cartilage strut for support of septum and lengthening of columella . A concomitant iliac bone graft is taken to reconstruct the alveolar bone . This group age will be above 8 years .~* Group (B) : Patients who present early before age of 8 years will have rhinoplasty session only . Another session will be prepared for cleft alveolus at age of 8 years .
Study NCT05619705 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy for Two-Health Coaching (H42)
Description: The H42-HV intervention includes health coaching calls, H42 web based app, mobile phone-based tracking.
Study NCT05619705 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Maintain Healthy in Pregnancy and Postpartum(mHIPP)
Description: A brief video on maternal warning signs that is available in English or Spanish.
Study NCT06311721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (US)
Description: Intravenous administration
Study NCT06311721 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (EU)
Description: Intravenous administration
Study NCT06065995 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: StoMakker
Description: A mobile application that offers age dependent information, a peer support platform and a game
Study NCT05139316 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DTX401
Description: nonreplicating, recombinant, adeno-associated virus (AAV) serotype 8 (AAV8)